Cloudpharm announces the approval of the funded project “Cloudscreen” in collaboration with the Institute of Chemical Biology of the National Hellenic Research Foundation (NHRF). The objective of the project is the development of a next generation “one-stop-shop”...
andreas
OSTEOME Project initiated, aiming at the development of a microbiome targeting dietary supplement
Cloudpharm announces the approval of the funded project “OSTEOME” in collaboration with the Musculoskeletal Diseases Research Laboratory “Th. Garofalidis ”of the Medical School of EKPA, the Institute of Chemical Biology of the National Research Foundation (NHRF), the...
Editorial on “How far have we come with contextual data integration in drug discovery”
In this editorial, we argue for a holistic view of evidence-based practices via the synergy of human and artificial intelligence in drug discovery. This strategy may build a collaborative conceptual framework to enable better-informed and rapid decisions, and the...
Publication on as new leads for the treatment of candidiasis
In this work, Cloupharm has been involved in the discovery of four compounds through a virtual screening procedure as putative sterol 14α-demethylase (CYP51) Candida albicans inhibitors. The compounds had the ability to inhibit growth of C. albicans cells and one was...
New scaffolds for angiotensin II receptor antagonism
In this study, Cloudpharm participated in a study for the discovery of novel agents bearing different scaffolds which may evolve as a new class of AT1 receptor antagonists. Nowadays, AT1 receptor (AT1R) antagonists (ARBs) constitute the one of the most prevalent...
Cloudpharm supports the “Targeted Drug Discovery” workshop
Cloudpharm supports the “Targeted Drug Discovery” workshop, which is the first interactive workshop in Greece focusing on the Drug design and development pipeline aiming to integrate all the related topics from structure-based drug design to preclinical evaluation.